GlassScriptPhysician profile
Gabriel B Herman
NPI 1437231289
$11,920.95
in general payments reported to CMS, 2019-2025
42 companies · $2,867 in 2025
The $2,867 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $103 · 2021: $1,147 · 2022: $2,319 · 2023: $2,559 · 2024: $2,577 · 2025: $2,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,898 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,898.43 |
| Education | $104.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,424.94 | 2019-2025 | |
| Janssen Biotech, INC. | $1,518.20 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $894.96 | 2021-2024 | Zeposia, Zerit |
| Pfizer INC. | $881.10 | 2019-2025 | |
| Gilead Sciences, INC. | $669.23 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $650.54 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $646.66 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $445.18 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $442.27 | 2022-2025 | |
| Madrigal Pharmaceuticals | $405.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $295.69 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $257.99 | 2021-2023 | Sucraid |
| Ardelyx, INC. | $195.50 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $190.37 | 2022-2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Redhill Biopharma INC. | $187.67 | 2021-2023 | Aemcolo, Movantik, Talicia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $166.22 | 2023 | Es2 Spinal System, Stryker Nav3i, Tritanium |
| Lilly USA, LLC | $156.49 | 2024-2025 | Omvoh |
| Otsuka America Pharmaceutical, INC. | $124.76 | 2023 | Nuedexta, Rexulti |
| Novo Nordisk INC | $122.95 | 2023-2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $121.77 | 2022 | |
| Sandoz INC. | $106.44 | 2023-2025 | Hyrimoz |
| Intercept Pharmaceuticals, INC. | $103.03 | 2023-2025 | Ocaliva |
| Celltrion USA INC. | $98.37 | 2023-2025 | Yuflyma, Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $94.64 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.30 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $82.15 | 2021-2024 | Dificid |
| Organon LLC | $72.85 | 2023-2024 | Hadlima |
| Vivus LLC | $65.73 | 2024-2025 | Pancreaze, Qsymia |
| Ipsen Biopharmaceuticals, INC | $64.27 | 2024-2025 | Iqirvo, Bylvay |
| Blueprint Medicines Corporation | $58.36 | 2023 | |
| Enterra Medical, INC. | $37.97 | 2024 | |
| W. L. Gore & Associates, INC. | $36.07 | 2022 | |
| Aimmune Therapeutics, INC. | $32.05 | 2024 | |
| Echosens North America, INC. | $25.00 | 2023 | Fibroscan |
| Ethicon US, LLC | $23.87 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.28 | 2021 | |
| Ferring Pharmaceuticals INC. | $22.01 | 2022 | |
| Pharming Healthcare, INC. | $19.82 | 2024 | Ruconest |
| Astrazeneca Pharmaceuticals LP | $19.44 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.74 | 2021 | |
| Olympus America INC. | $16.46 | 2025 | Single Use Repositionable Clip |
| Braintree Laboratories, INC. | $15.56 | 2025 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.